Latest Headlines

Latest Headlines

Surprise: Merck's cholesterol combo Vytorin hits goal in long-awaited outcomes trial

Merck & Co.'s cholesterol drug Vytorin hit its goal in a long-awaited outcomes trial, beating solo statin therapy at cutting cardiovascular risk. It's a vindication for the company, which endured a storm of criticism about an earlier trial in which Vytorin fell short.

Merck's head-to-head Vytorin trial might be surprisingly flattering

Merck & Co. just disclosed some welcome news for its own investors--and potentially for competitors, too. Not to mention all the market watchers ready for the long IMPROVE-IT trial saga to come to an end.

AstraZeneca wins, Merck and AbbVie lose with new statin-use guidelines

New rules for prescribing statin drugs could double the number of people taking them--or not. They could help AstraZeneca pump up sales of its high-powered Crestor--or not. What they will do--most likely--is undercut Merck's cholesterol drugs Vytorin and Zetia, along with AbbVie's fenofibrate-based lipid meds TriCor and Trilipix.

Suffering from generic onslaught, Merck cuts sales forecast

Merck cut its sales forecast and posted a 50% drop in quarterly earnings as it continues to absorb major hits to its once-blockbuster Singulair. The fact that profits beat analyst expectations says as much about those expectations as it does about Merck's performance for the quarter.

Big Kahuna statins gobble up bigger share of cholesterol market

No question, statins are the big gorilla of the cholesterol-fighting drug market. And as  Forbes  reports today, that drug class is marking out an even bigger territory as time goes by. Over the past 5 years, statin prescriptions have grown by 17% to 214 million a year, while other cholesterol remedies lost 28% of their scripts. Now, those other drugs only account for 50 million prescriptions a year.

Merck wins FDA nod for new Zetia-Lipitor combo, despite lack of outcomes benefit

Merck will soon launch a new cholesterol combo that melds its Zetia drug with generic Lipitor. The Zetia-plus-statin approach isn't new, of course; Merck already sells Vytorin, a combination of Zetia and its own off-patent statin Zocor, known generically as Simvastatin.

Analysts cheer decision to continue Merck's controversial Vytorin study

The huge late-stage study that is seeking to determine once and for all if Merck's combo cholesterol drug Vytorin actually works and is safe will run its full course now that an independent safety board has signed off following a review of the data.

Merck gets green light to continue Vytorin outcomes trial

The Vytorin outcomes trial will go on. That's all the information we're getting out of the enormous Improve-It study for now. An independent data monitoring board looked at the trial's results so far and recommended that it continue.

Merck to pay $688M in lawsuit over failed Vytorin study

Merck agreed to pay $688 million to resolve two securities-fraud lawsuits filed by irate shareholders. Pension funds and other institutional investors alleged that Merck--and Schering-Plough, which Merck bought in 2009--held back key information about the Enhance trial, which tested the combination drug Vytorin against one of its constituent parts, the statin drug Zocor.

Court spoons out good news for Merck investors

After having to swallow a pretty bitter pill last week from a bad earnings report and sorry looking forecast, Merck investors got a taste of sugar, about $2 billion worth.